Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

What happened

Enanta Pharmaceuticals said the first patient has been dosed in RESOLVE, its global Phase 2b/3 study of zelicapavir in adults at high risk of severe RSV outcomes. Topline data from the Phase 2b portion are expected in 2027.

Confirmed

Global impact / market context

Dosing the first patient moves zelicapavir from earlier testing into a larger late-stage trial, a step that can raise research spending before any revenue arrives. Positive results would be needed to justify that cost and support the drug's path toward regulatory review.

Analyst inference

The article says no approved RSV antiviral therapies are currently available, so zelicapavir could address an unmet need. Investors may treat the 2027 Phase 2b readout as the key catalyst, since trial delays or weak results would affect expectations for the company's pipeline.

Analyst inference

What to watch

1. Enanta expects topline data from the RESOLVE Phase 2b portion in 2027, and the LOTUS pediatric Phase 2b trial is also positioned to deliver data that year. Confirmed
2. Watch whether Enanta discloses enrollment pace and study costs, because slow recruitment or rising trial expenses would increase cash use before the 2027 data readout. Proposed
3. A strong Phase 2b result would strengthen the case for zelicapavir in high-risk adults and could support partnership or funding talks, while weak results would reduce the pipeline's perceived value. Analyst inference

Evidence

• Original source link unavailable